Ectopic Male Breast Cancer in Suprapubic Area That Relapsed with Hematogenous Metastasis

Tough ectopic male breast cancer is extremely rare, non-axillary ectopic male breast cancer is even rare. To date, the natural course and prognosis of this disease are not fully understood. Consequently, the appropriate treatment for this disease has not been established. We report on a patient with...

Full description

Saved in:
Bibliographic Details
Published inJournal of breast cancer Vol. 24; no. 3; pp. 344 - 348
Main Authors Byon, Jung Hee, An, Ae Ri, Shin, Jin Yong, Choi, Eun Jung
Format Journal Article
LanguageEnglish
Published Korean Breast Cancer Society 01.06.2021
한국유방암학회
Subjects
Online AccessGet full text
ISSN1738-6756
2092-9900
DOI10.4048/jbc.2021.24.e21

Cover

More Information
Summary:Tough ectopic male breast cancer is extremely rare, non-axillary ectopic male breast cancer is even rare. To date, the natural course and prognosis of this disease are not fully understood. Consequently, the appropriate treatment for this disease has not been established. We report on a patient with ectopic male breast cancer in the suprapubic area that relapsed with hematogenous metastasis 3 years after complete surgical resection and adjuvant treatment despite an early diagnosis. This unusual case highlights the need for new prognostic factors such as genomic profiling to predict whether ectopic male breast cancer is aggressive and to guide on the duration between follow-ups and the appropriate method for conducting them.Tough ectopic male breast cancer is extremely rare, non-axillary ectopic male breast cancer is even rare. To date, the natural course and prognosis of this disease are not fully understood. Consequently, the appropriate treatment for this disease has not been established. We report on a patient with ectopic male breast cancer in the suprapubic area that relapsed with hematogenous metastasis 3 years after complete surgical resection and adjuvant treatment despite an early diagnosis. This unusual case highlights the need for new prognostic factors such as genomic profiling to predict whether ectopic male breast cancer is aggressive and to guide on the duration between follow-ups and the appropriate method for conducting them.
Bibliography:ObjectType-Case Study-2
SourceType-Scholarly Journals-1
ObjectType-Feature-4
content type line 23
ObjectType-Report-1
ObjectType-Article-3
https://ejbc.kr/DOIx.php?id=10.4048/jbc.2021.24.e21
ISSN:1738-6756
2092-9900
DOI:10.4048/jbc.2021.24.e21